BioMedNewsBreaks

ThursdayNov 03, 2022 12:58 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Announces Expansion of Executive Team

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, is expanding its executive team. The expansion is part of ODYY’s support of and commitment to Odyssey NeuroPharma, the company’s newest entity. Additions to the executive team include Erik Emerson, named chief commercial officer, and Greg Gironda, named chief operating officer. These two together have more than five decades of experience in commercializing innovative pharmaceutical compounds with leading pharmaceutical companies; the pair will work to advance Odyssey’s concussion treatment and Niemann-Pick treatment. According to the announcement, more than 5 million…

Continue Reading

ThursdayNov 03, 2022 11:16 am

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation Schedule for Upcoming Investor Events

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced its participation in upcoming investor events. The company’s Chief Executive Officer Doug Drysdale will present and host investor meetings at the Jefferies London Healthcare Conference taking place on Nov. 15-17, 2022. Drysdale’s presentation is slated to begin at 8:00 a.m. GMT on Nov. 15. Drysdale will also participate in a panel discussion titled “Psychedelics Landscape – What can we expect?” at 5:00 p.m. GMT on Nov. 16, 2022, at the Pinsent Masons Psychedelics Panel in London, U.K. In addition, Drysdale will participate in…

Continue Reading

WednesdayNov 02, 2022 12:45 pm

BioMedNewsBreaks – MetAlert Inc. (MLRT) Selects POD Group’s Advanced Connectivity Solutions for SmartSole(TM) Platform

MetAlert (OTC: MLRT), a pioneer in the field of wearable GPS human and asset tracking and remote patient monitoring, has selected Pod Group’s ENO ONE IoT SIM cards and advanced connectivity solutions for enterprise IoT applications for its award-winning, two-way GPS SmartSole. A wearable medical monitoring device, SmartSole is integrated into an orthotic insole allowing discreet and unobtrusive tracking and remote monitoring of Alzheimer’s, dementia and autism sufferers. “The POD Group partnership is a critical component for the launch of our SmartSole plus, a mobile hot spot connected to other wearable devices,” said MetAlert CEO Patrick Bertagna. “This level of…

Continue Reading

WednesdayNov 02, 2022 11:53 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Doses First Patient in Global Berubicin Trial Evaluating GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has provided an update on enrollment of its ongoing trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. The company announced that the first patient in Europe has been enrolled in the study and has started receiving dosages. Eventually the company plans to have 68 sites opened for the ongoing…

Continue Reading

TuesdayNov 01, 2022 12:58 pm

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Exec to Present at Neuropsychiatric & Psychedelics Drug Development Summit

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the 5th annual Neuropsychiatric & Psychedelics Drug Development Summit. The summit runs through Nov. 2, 2022, and is being held in Boston. Cybin director of neuropharmacology Amy Reichelt, PhD, will present during the event; her presentation, titled “CYB004 — Modifications to DMT to Enhance its Therapeutic Potential,” includes an overview of the preclinical data for CYB004, Cybin’s deuterated dimethyltryptamine (DMT) program and the advantages of deuteration on its therapeutic effect. Reichelt’s presentation will begin at 1:15 p.m. ET today.“I am delighted to be…

Continue Reading

TuesdayNov 01, 2022 10:42 am

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Files for Patent Protection on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

Odyssey Health (OTC: ODYY) has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As previously announced, Odyssey’s recently completed phase I study to treat concussion successfully used Odyssey’s Nasal Device and drug combination. “We were very pleased with the functionality and performance of the Nasal Device during the phase I study and its administration of Odyssey’s PRV-002 concussion drug,” said Michael Redmond, CEO of Odyssey. “The ability to get drugs for neurological conditions delivered directly into the brain rapidly at effective levels while simultaneously having less concern for side effects…

Continue Reading

MondayOct 31, 2022 2:42 pm

BioMedNewsBreaks – Quad M Solutions Inc. (MMMM) Commences Application to Dual List on Upstream

Quad M Solutions (OTC: MMMM), a staffing company providing modern health care solution benefits, today announced that it has begun the application process for dual listing on Upstream, the next-generation trading app for digital securities and NFTs powered by Horizon Fintex (“Horizon”) and MERJ Exchange Limited (“MERJ”). According to the update, the planned dual listing is designed to provide Quad M with the opportunity to access a global, digital-first investor base that can trade using the USDC digital currency along with credit, debit, PayPal, and USD, unlocking liquidity and enhancing price discovery while globalizing the opportunity to invest in OTC-listed…

Continue Reading

MondayOct 31, 2022 1:52 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Shows Superior Performance to Other Anthracyclines, Standards of Care for GBM

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical innovator staking out its own position within the competitive field of research, having already progressed to human trials evaluating its novel glioblastoma multiforme (“GBM”) solution, known as Berubicin (or WP744). “Berubicin is a patented doxorubicin (‘Dox’) analog – an anthracycline chemotherapy agent novel in its ability to cross the blood-brain barrier to target tumors directly. Tested against Dox in cancer cells, Berubicin showed a greater capacity to destroy or damage the cancers. In models evaluating intracranial gliomas, Berubicin showed a greater capacity to prolong life than temozolomide, another standard of care for GBM,”…

Continue Reading

MondayOct 31, 2022 1:12 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Pleased with Safety Profile of Its PRV-002 Concussion Treatment

Odyssey Health (OTC: ODYY) recently announced the completion of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial. “Odyssey’s trial involved administering its novel drug to treat concussions, PRV-002, to healthy human subjects to determine drug safety. A total of 40 healthy subjects took part in the study. In Cohort I, eight patients received a low dose of the drug, and in Cohort II, patients received a high dose of the drug. The second Cohort reflected the success of the first, where the drug was well tolerated and proved safe with no severe adverse events reported,”…

Continue Reading

ThursdayOct 27, 2022 11:37 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Graduates Class of Facilitators

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its EMBARK Psychedelic-Assisted Psychotherapy Training Program have announced the graduation of highly skilled facilitators who are now prepared to handle a range of experiences that participants of psychedelic-assisted psychotherapy may undergo. The training program includes foundational training enabling participants to learn the skills necessary to provide ethical care for and work with psychedelic-assisted psychotherapy patients. EMBARK is a leading-edge model of psychedelic-assisted psychotherapy that is implemented in Cybin’s phase 1/2a trial, which is designed to evaluate CYB003, Cybin’s investigational deuterated psilocybin analog. CYB003 has potential to…

Continue Reading